Minimal Residual Disease and HCT (Myeloma and Leukemia)

Track: BMT Pharmacists Conference
Saturday, March 1, 2014, 9:00 AM-10:00 AM
Grapevine A (Gaylord Texan)
Sergio Giralt, MD , Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY
Audio File Recorded Presentation
Disclosures:
S. Giralt, Celgene, Consultant: Consultancy, Honoraria and Research Funding
Bioline, Consultant: Advisory Board, Consultancy and Honoraria
Janssen, Consultant: Advisory Board, Consultancy and Honoraria
Onyx, Consultant: Advisory Board, Consultancy and Honoraria
Sanofi, Consultant: Advisory Board, Consultancy and Honoraria
Seattle Genetics, Consultant: Advisory Board, Consultancy and Honoraria
Skyline Diagnostics, Consultant: Advisory Board, Consultancy and Honoraria
Spectrum Pharmaceuticals, Consultant: Advisory Board, Consultancy and Honoraria
See more of: (PHARM) Minimal Residual Disease and HCT (Myeloma and Leukemia)
See more of: BMT Pharmacists Conference